Jackson Square Capital LLC purchased a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 72,456 shares of the company’s stock, valued at approximately $1,596,000.
Several other institutional investors also recently made changes to their positions in CLBT. FMR LLC raised its position in shares of Cellebrite DI by 136.3% in the 3rd quarter. FMR LLC now owns 5,616,757 shares of the company’s stock worth $94,586,000 after buying an additional 3,239,307 shares during the period. Meitav Investment House Ltd. increased its stake in Cellebrite DI by 29.7% during the third quarter. Meitav Investment House Ltd. now owns 2,066,322 shares of the company’s stock worth $34,797,000 after acquiring an additional 473,293 shares during the last quarter. Pembroke Management LTD raised its holdings in shares of Cellebrite DI by 24.3% in the 3rd quarter. Pembroke Management LTD now owns 1,908,345 shares of the company’s stock worth $32,137,000 after purchasing an additional 372,619 shares during the period. Principal Financial Group Inc. acquired a new position in shares of Cellebrite DI in the 3rd quarter valued at about $23,402,000. Finally, Two Sigma Advisers LP grew its holdings in shares of Cellebrite DI by 9.8% during the 3rd quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company’s stock worth $22,584,000 after purchasing an additional 120,000 shares during the period. 45.88% of the stock is owned by hedge funds and other institutional investors.
Cellebrite DI Price Performance
NASDAQ:CLBT opened at $22.78 on Friday. The firm has a 50-day moving average of $20.76 and a two-hundred day moving average of $17.60. Cellebrite DI Ltd. has a 1-year low of $8.23 and a 1-year high of $23.50.
Analysts Set New Price Targets
CLBT has been the topic of a number of recent research reports. Craig Hallum lifted their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. upped their price target on shares of Cellebrite DI from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. Needham & Company LLC raised their price objective on Cellebrite DI from $17.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, TD Cowen upped their target price on Cellebrite DI from $20.00 to $23.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Cellebrite DI has an average rating of “Buy” and an average target price of $20.57.
Check Out Our Latest Report on Cellebrite DI
About Cellebrite DI
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
See Also
- Five stocks we like better than Cellebrite DI
- What is a Low P/E Ratio and What Does it Tell Investors?
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- How to Plot Fibonacci Price Inflection Levels
- MarketBeat Week in Review – 01/13 – 01/17
Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report).
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.